The non-medical use and trafficking of tramadol remain most concentrated in North Africa, West and Central Africa, and the Near and Middle East and South-West Asia, though there remains significant localized non-medical use in other regions.There remains a significant data gap on tramadol use and…
Similarly to most internationally controlled drugs, the use of NPS among adolescents is higher than among the general population, but the difference between adolescent boys and girlsis lower for NPS than for controlled drugs.Limited data suggest that NPS use is generally higher among school…
The health harms posed by the non-medical use of opioids remains high in North America, but have started to decline in late 2023 and in 2024.Opioid overdose deaths reached historical highs in the United States of America and Canada between 2021 and 2023 but have since started to decline, returning…
Opioid-related harms, measured as new people entering treatment, have declined in Europe.Although the share of people in treatment for opioid use disorders remains substantial in Europe, the number of people entering treatment for the first time has decreased.In Eastern Europe and South-Eastern…
In East and South-East Asia, limited regular data collection makes it difficult to assess long-term trends in opioid use. However, data on people registered for drug use and people in drug treatment indicate a decline in opioid (mainly heroin) use over the past 10 to 15 years.In most of East and…
Opioids and cannabis account for the greatest overall harm globally, though the severity of impacts differs.Combined evidence from country rankings of most harmful drugs and global indicators on deaths, drug use disorders and people in drug-related treatment point to opioids and cannabis resulting…
Globally, the majority of people in drug-related treatment continue to be men, although the proportion of women varies by region, subregion and primary drug.Approximately one in five people in drug-related treatment worldwide is a woman.The lowest proportions of women in drug-related treatment are…
The global burden of caring for people who inject drugs with evidence-informed interventions remains highIn 2024, there were an estimated 14.3 million people who inject drugs, or 0.3 per cent of the population aged 15–64.The highest prevalence of people who inject drugs (PWID) remain in Eastern…
HIV prevalence remains high among people who inject drugs, with significant disparities by sex and region.People who inject drugs face a relatively much higher risk of HIV infection – around 14 times that of the global population aged 15-64 – with particularly elevated risks for women and young…
Hepatitis remains a major health burden among people who inject drugs.Injecting drug use remains a major contributor to the global hepatitis C epidemic, with nearly half (48 per cent) of people who inject drugs – around 7 million – living with hepatitis C in 2024.The highest prevalence of hepatitis…
Polydrug use is common among people in drug treatment, with patterns varying by region.According to the limited data available on people in drug treatment, between 40 and 50 per cent of persons in drug-related treatment are polydrug users, with lower levels in Asia (22 per cent) and almost no…
Polydrug use poses significant risks and is more common among people with drug use disorders.No consensus definition of polydrug use currently exists but it can be generally understood as taking two or more drugs together or in sequence (intentionally or unintentionally), with both forms increasing…
